Public Health Product Hops
Bill of Health
APRIL 24, 2023
Regulatory and patent exclusivity periods govern the timing of generic entry, and because market share and revenue is often quickly lost upon market entry of generic drugs, extending market exclusivity for any duration can be extremely profitable. Could Congress or the FDA have incentivized the manufacturer to initiate the switch much sooner?
Let's personalize your content